Literature DB >> 24852394

PL03.05 An intergroup randomized phase III comparison of standard-dose (60 Gy) vs high-dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24852394

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  5 in total

1.  Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy.

Authors:  Fang Shi; Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Cancer Biol Ther       Date:  2017-03-04       Impact factor: 4.742

2.  Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report.

Authors:  Di Liu; Yu-Xin Shen; Wei-Xin Zhao; Guo-Liang Jiang; Jia-Yan Chen; Min Fan
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

3.  Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?

Authors:  Els Wauters; Johan Vansteenkiste
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

4.  A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.

Authors:  Anne-Marie C Dingemans; Gerben Bootsma; Angela van Baardwijk; Bart Reymen; Rinus Wanders; Boudewijn Brans; Marco Das; Monique Hochstenbag; Arne van Belle; Ruud Houben; Philippe Lambin; Dirk de Ruysscher
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

5.  Simultaneous integrated dose reduction intensity-modulated radiotherapy applied to an elective nodal area of limited-stage small-cell lung cancer.

Authors:  Zhiyan Liu; Weishuai Liu; Kai Ji; Ping Wang; Xin Wang; Lujun Zhao
Journal:  Exp Ther Med       Date:  2015-10-30       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.